Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franck Morschhauser

Showing results (41-50 of 315) with videos related to

Pageof 32
Sort By:
Oncoimmunology|April 11, 2018
NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatmentDang-Nghiem Vo, Catherine Alexia, Nerea Allende-Vega, et al.
Blood|September 5, 2008
Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosisVincent Ribrag, Serge Koscielny, Olivier Casasnovas, et al.
Cancer|December 24, 2009
Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study GroupIrene Biasoli, Aspasia Stamatoullas, Véronique Meignin, et al.
Hematological Oncology|May 22, 2025
Investigating the Association Between a Continuous Variable and a Time-To-Event Outcome: Going Beyond the Cut-Off ApproachTesla Murairi Mirimo, Cédric Portugues, Laurent Remontet, et al.
Leukemia & Lymphoma|March 29, 2011
Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphomaPeter Borchmann, Raoul Herbrecht, Martin Wilhelm, et al.
Cancers|August 10, 2024
Phase IB Study of Oral Selinexor in Combination with Rituximab and Platinum Chemotherapy in Patients with Relapsed/Refractory B-Cell Lymphoma-Final AnalysisMarie Maerevoet, Olivier Casasnovas, Guillaume Cartron, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 18, 2021
Bartonellosis mimicking post-transplant lymphoproliferative diseasesEileen M Boyle, Clio Baillet, Céline Dupré, et al.
Investigational New Drugs|January 21, 2015
Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemiaFranck Morschhauser, Louis Terriou, Bertrand Coiffier, et al.
Journal of Thrombosis and Haemostasis : JTH|September 14, 2020
Effects of novel Btk and Syk inhibitors on platelet functions alone and in combination in vitro and in vivoJennifer Series, Agnès Ribes, Cédric Garcia, et al.
Blood|July 12, 2013
Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)John Radford, Andrew Davies, Guillaume Cartron, et al.
Pageof 32

Showing results (41-50 of 315) with videos related to

Sort By:
Pageof 32
Oncoimmunology|April 11, 2018
NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatmentDang-Nghiem Vo, Catherine Alexia, Nerea Allende-Vega, et al.
Blood|September 5, 2008
Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosisVincent Ribrag, Serge Koscielny, Olivier Casasnovas, et al.
Cancer|December 24, 2009
Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study GroupIrene Biasoli, Aspasia Stamatoullas, Véronique Meignin, et al.
Hematological Oncology|May 22, 2025
Investigating the Association Between a Continuous Variable and a Time-To-Event Outcome: Going Beyond the Cut-Off ApproachTesla Murairi Mirimo, Cédric Portugues, Laurent Remontet, et al.
Leukemia & Lymphoma|March 29, 2011
Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphomaPeter Borchmann, Raoul Herbrecht, Martin Wilhelm, et al.
Cancers|August 10, 2024
Phase IB Study of Oral Selinexor in Combination with Rituximab and Platinum Chemotherapy in Patients with Relapsed/Refractory B-Cell Lymphoma-Final AnalysisMarie Maerevoet, Olivier Casasnovas, Guillaume Cartron, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 18, 2021
Bartonellosis mimicking post-transplant lymphoproliferative diseasesEileen M Boyle, Clio Baillet, Céline Dupré, et al.
Investigational New Drugs|January 21, 2015
Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemiaFranck Morschhauser, Louis Terriou, Bertrand Coiffier, et al.
Journal of Thrombosis and Haemostasis : JTH|September 14, 2020
Effects of novel Btk and Syk inhibitors on platelet functions alone and in combination in vitro and in vivoJennifer Series, Agnès Ribes, Cédric Garcia, et al.
Blood|July 12, 2013
Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)John Radford, Andrew Davies, Guillaume Cartron, et al.
Pageof 32